Resources from the same session
124O - Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial
Presenter: Mafalda Oliveira
Session: Proffered Paper session 2: Best abstracts
Resources:
Abstract
Slides
Webcast
189O - A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
Presenter: Barbara Pistilli
Session: Proffered Paper session 2: Best abstracts
Resources:
Abstract
Slides
Webcast
Invited Discussant 124O and 189O
Presenter: Rebecca Dent
Session: Proffered Paper session 2: Best abstracts
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Proffered Paper session 2: Best abstracts
Resources:
Webcast
LBA1 - Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
Presenter: Carlos Barrios
Session: Proffered Paper session 2: Best abstracts
Resources:
Abstract
Slides
Webcast
123O - Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52 / ATHENE)
Presenter: Gabriel Rinnerthaler
Session: Proffered Paper session 2: Best abstracts
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1 and 123O
Presenter: Matteo Lambertini
Session: Proffered Paper session 2: Best abstracts
Resources:
Slides
Webcast